Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATTE
NCT01641809Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cabotegravir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/mL at 48 weeks. Started Aug 2012; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01641809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641809.